Implementation Study of Patient-Ready Syringes Containing 25 mg/mL Methotrexate Solution for Use in Treating Ectopic Pregnancy
Background. Ectopic pregnancy (EP) is a significant cause of morbidity and mortality during the first trimester of pregnancy. Small unruptured tubal pregnancies can be treated medically with a single dose of methotrexate (MTX). Objective. The aim of this study was to evaluate the stability of a 25 m...
Gespeichert in:
| Veröffentlicht in: | BioMed research international 2014-01, Vol.2014 (2014), p.1-4 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4 |
|---|---|
| container_issue | 2014 |
| container_start_page | 1 |
| container_title | BioMed research international |
| container_volume | 2014 |
| creator | Respaud, Renaud Gaudy, A. S. Arlicot, C. Tournamille, J. F. Viaud-Massuard, M. C. Elfakir, C. Antier, Daniel |
| description | Background. Ectopic pregnancy (EP) is a significant cause of morbidity and mortality during the first trimester of pregnancy. Small unruptured tubal pregnancies can be treated medically with a single dose of methotrexate (MTX). Objective. The aim of this study was to evaluate the stability of a 25 mg/mL solution of MTX to devise a secure delivery circuit for the preparation and use of this medication in the management of EP. Method. MTX solutions were packaged in polypropylene syringes, stored over an 84-day period, and protected from light either at +2 to +8°C or at 23°C. We assessed the physical and chemical stability of the solutions at various time points over the storage period. A pharmaceutical delivery circuit was implemented that involved the batch preparation of MTX syringes. Results. We show that 25 mg/mL MTX solutions remain stable over an 84-day period under the storage conditions tested. Standard doses were prepared, ranging from 50 mg to 100 mg. The results of this study suggest that MTX syringes can be prepared in advance by the pharmacy, ready to be dispensed at any time that a diagnosis of EP is made. Conclusion. The high stability of a 25 mg/mL MTX solution in polypropylene syringes makes it possible to implement a flexible and cost-effective delivery circuit for ready-to-use preparations of this drug, providing 24-hour access and preventing treatment delays. |
| doi_str_mv | 10.1155/2014/689308 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4037123</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A427024063</galeid><sourcerecordid>A427024063</sourcerecordid><originalsourceid>FETCH-LOGICAL-c527t-15b83fd3a9e7d8ff2ecc57f8f26ecc86bfffb2c2fb8463a62d5957563aaf68213</originalsourceid><addsrcrecordid>eNqFkk1v0zAYgCMEYtPYiTPIEhcECvV3nAvSVA2YVMREt7PlOq9TT4ldnATobVf-Jr8El47yccEXv7YfP_Zrv0XxmOBXhAgxo5jwmVQ1w-pecUwZ4aUknNw_xIwdFafDcINzU0TiWj4sjiivMa6r6ri4veg3HfQQRjP6GNBynJotig5d5nGeLT-CyRPLbfKhhQHNYyZ9yANExffbb3076xfoPYzrOCb4akZAy9hNP10uJnQ9APIBXSXIvrzp3I5x4y26TNAGE-z2UfHAmW6A07v-pLh-c341f1cuPry9mJ8tSitoNZZErBRzDTM1VI1yjoK1onLKUZkjJVfOuRW11K0Ul8xI2ohaVCKHxklFCTspXu-9m2nVQ2Nzbsl0epN8b9JWR-P13yvBr3UbP2uOWUUoy4Lnd4IUP00wjLr3g4WuMwHiNGgipFSi5opm9Nk_6E2cUsjpZYpXNeVS1L-p1nSgfXD5BY3dSfUZpxWmHMvdsS_3lE1xGBK4w5UJ1rsS0LsS0PsSyPTTP7M8sL8-PAMv9sDah8Z88f-xPdnDkBFw5gBnW0Ux-wE6F8Qp</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1547924659</pqid></control><display><type>article</type><title>Implementation Study of Patient-Ready Syringes Containing 25 mg/mL Methotrexate Solution for Use in Treating Ectopic Pregnancy</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Respaud, Renaud ; Gaudy, A. S. ; Arlicot, C. ; Tournamille, J. F. ; Viaud-Massuard, M. C. ; Elfakir, C. ; Antier, Daniel</creator><contributor>Horne, Andrew</contributor><creatorcontrib>Respaud, Renaud ; Gaudy, A. S. ; Arlicot, C. ; Tournamille, J. F. ; Viaud-Massuard, M. C. ; Elfakir, C. ; Antier, Daniel ; Horne, Andrew</creatorcontrib><description>Background. Ectopic pregnancy (EP) is a significant cause of morbidity and mortality during the first trimester of pregnancy. Small unruptured tubal pregnancies can be treated medically with a single dose of methotrexate (MTX). Objective. The aim of this study was to evaluate the stability of a 25 mg/mL solution of MTX to devise a secure delivery circuit for the preparation and use of this medication in the management of EP. Method. MTX solutions were packaged in polypropylene syringes, stored over an 84-day period, and protected from light either at +2 to +8°C or at 23°C. We assessed the physical and chemical stability of the solutions at various time points over the storage period. A pharmaceutical delivery circuit was implemented that involved the batch preparation of MTX syringes. Results. We show that 25 mg/mL MTX solutions remain stable over an 84-day period under the storage conditions tested. Standard doses were prepared, ranging from 50 mg to 100 mg. The results of this study suggest that MTX syringes can be prepared in advance by the pharmacy, ready to be dispensed at any time that a diagnosis of EP is made. Conclusion. The high stability of a 25 mg/mL MTX solution in polypropylene syringes makes it possible to implement a flexible and cost-effective delivery circuit for ready-to-use preparations of this drug, providing 24-hour access and preventing treatment delays.</description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2014/689308</identifier><identifier>PMID: 24900977</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Puplishing Corporation</publisher><subject>Accuracy ; Care and treatment ; Complications and side effects ; Dihydrofolate reductase ; Dilution ; Dosage and administration ; Drug dosages ; Drug Packaging - methods ; Drug Stability ; Drug therapy ; Female ; Good Manufacturing Practice ; Health aspects ; Hospitals ; Humans ; Medical treatment ; Methotrexate ; Methotrexate - chemistry ; Methotrexate - therapeutic use ; Patients ; Pharmaceutical Solutions - chemistry ; Pharmaceutical Solutions - therapeutic use ; Pharmaceuticals ; Pharmacy ; Polypropylenes - chemistry ; Pregnancy ; Pregnancy complications ; Pregnancy, Ectopic ; Pregnancy, Ectopic - drug therapy ; Prevention ; Syringes</subject><ispartof>BioMed research international, 2014-01, Vol.2014 (2014), p.1-4</ispartof><rights>Copyright © 2014 R. Respaud et al.</rights><rights>COPYRIGHT 2014 John Wiley & Sons, Inc.</rights><rights>Copyright © 2014 R. Respaud et al. R. Respaud et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2014 R. Respaud et al. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c527t-15b83fd3a9e7d8ff2ecc57f8f26ecc86bfffb2c2fb8463a62d5957563aaf68213</citedby><cites>FETCH-LOGICAL-c527t-15b83fd3a9e7d8ff2ecc57f8f26ecc86bfffb2c2fb8463a62d5957563aaf68213</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037123/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037123/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24900977$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Horne, Andrew</contributor><creatorcontrib>Respaud, Renaud</creatorcontrib><creatorcontrib>Gaudy, A. S.</creatorcontrib><creatorcontrib>Arlicot, C.</creatorcontrib><creatorcontrib>Tournamille, J. F.</creatorcontrib><creatorcontrib>Viaud-Massuard, M. C.</creatorcontrib><creatorcontrib>Elfakir, C.</creatorcontrib><creatorcontrib>Antier, Daniel</creatorcontrib><title>Implementation Study of Patient-Ready Syringes Containing 25 mg/mL Methotrexate Solution for Use in Treating Ectopic Pregnancy</title><title>BioMed research international</title><addtitle>Biomed Res Int</addtitle><description>Background. Ectopic pregnancy (EP) is a significant cause of morbidity and mortality during the first trimester of pregnancy. Small unruptured tubal pregnancies can be treated medically with a single dose of methotrexate (MTX). Objective. The aim of this study was to evaluate the stability of a 25 mg/mL solution of MTX to devise a secure delivery circuit for the preparation and use of this medication in the management of EP. Method. MTX solutions were packaged in polypropylene syringes, stored over an 84-day period, and protected from light either at +2 to +8°C or at 23°C. We assessed the physical and chemical stability of the solutions at various time points over the storage period. A pharmaceutical delivery circuit was implemented that involved the batch preparation of MTX syringes. Results. We show that 25 mg/mL MTX solutions remain stable over an 84-day period under the storage conditions tested. Standard doses were prepared, ranging from 50 mg to 100 mg. The results of this study suggest that MTX syringes can be prepared in advance by the pharmacy, ready to be dispensed at any time that a diagnosis of EP is made. Conclusion. The high stability of a 25 mg/mL MTX solution in polypropylene syringes makes it possible to implement a flexible and cost-effective delivery circuit for ready-to-use preparations of this drug, providing 24-hour access and preventing treatment delays.</description><subject>Accuracy</subject><subject>Care and treatment</subject><subject>Complications and side effects</subject><subject>Dihydrofolate reductase</subject><subject>Dilution</subject><subject>Dosage and administration</subject><subject>Drug dosages</subject><subject>Drug Packaging - methods</subject><subject>Drug Stability</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Good Manufacturing Practice</subject><subject>Health aspects</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Medical treatment</subject><subject>Methotrexate</subject><subject>Methotrexate - chemistry</subject><subject>Methotrexate - therapeutic use</subject><subject>Patients</subject><subject>Pharmaceutical Solutions - chemistry</subject><subject>Pharmaceutical Solutions - therapeutic use</subject><subject>Pharmaceuticals</subject><subject>Pharmacy</subject><subject>Polypropylenes - chemistry</subject><subject>Pregnancy</subject><subject>Pregnancy complications</subject><subject>Pregnancy, Ectopic</subject><subject>Pregnancy, Ectopic - drug therapy</subject><subject>Prevention</subject><subject>Syringes</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkk1v0zAYgCMEYtPYiTPIEhcECvV3nAvSVA2YVMREt7PlOq9TT4ldnATobVf-Jr8El47yccEXv7YfP_Zrv0XxmOBXhAgxo5jwmVQ1w-pecUwZ4aUknNw_xIwdFafDcINzU0TiWj4sjiivMa6r6ri4veg3HfQQRjP6GNBynJotig5d5nGeLT-CyRPLbfKhhQHNYyZ9yANExffbb3076xfoPYzrOCb4akZAy9hNP10uJnQ9APIBXSXIvrzp3I5x4y26TNAGE-z2UfHAmW6A07v-pLh-c341f1cuPry9mJ8tSitoNZZErBRzDTM1VI1yjoK1onLKUZkjJVfOuRW11K0Ul8xI2ohaVCKHxklFCTspXu-9m2nVQ2Nzbsl0epN8b9JWR-P13yvBr3UbP2uOWUUoy4Lnd4IUP00wjLr3g4WuMwHiNGgipFSi5opm9Nk_6E2cUsjpZYpXNeVS1L-p1nSgfXD5BY3dSfUZpxWmHMvdsS_3lE1xGBK4w5UJ1rsS0LsS0PsSyPTTP7M8sL8-PAMv9sDah8Z88f-xPdnDkBFw5gBnW0Ux-wE6F8Qp</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Respaud, Renaud</creator><creator>Gaudy, A. S.</creator><creator>Arlicot, C.</creator><creator>Tournamille, J. F.</creator><creator>Viaud-Massuard, M. C.</creator><creator>Elfakir, C.</creator><creator>Antier, Daniel</creator><general>Hindawi Puplishing Corporation</general><general>Hindawi Publishing Corporation</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AFFIF</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20140101</creationdate><title>Implementation Study of Patient-Ready Syringes Containing 25 mg/mL Methotrexate Solution for Use in Treating Ectopic Pregnancy</title><author>Respaud, Renaud ; Gaudy, A. S. ; Arlicot, C. ; Tournamille, J. F. ; Viaud-Massuard, M. C. ; Elfakir, C. ; Antier, Daniel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c527t-15b83fd3a9e7d8ff2ecc57f8f26ecc86bfffb2c2fb8463a62d5957563aaf68213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Accuracy</topic><topic>Care and treatment</topic><topic>Complications and side effects</topic><topic>Dihydrofolate reductase</topic><topic>Dilution</topic><topic>Dosage and administration</topic><topic>Drug dosages</topic><topic>Drug Packaging - methods</topic><topic>Drug Stability</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Good Manufacturing Practice</topic><topic>Health aspects</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Medical treatment</topic><topic>Methotrexate</topic><topic>Methotrexate - chemistry</topic><topic>Methotrexate - therapeutic use</topic><topic>Patients</topic><topic>Pharmaceutical Solutions - chemistry</topic><topic>Pharmaceutical Solutions - therapeutic use</topic><topic>Pharmaceuticals</topic><topic>Pharmacy</topic><topic>Polypropylenes - chemistry</topic><topic>Pregnancy</topic><topic>Pregnancy complications</topic><topic>Pregnancy, Ectopic</topic><topic>Pregnancy, Ectopic - drug therapy</topic><topic>Prevention</topic><topic>Syringes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Respaud, Renaud</creatorcontrib><creatorcontrib>Gaudy, A. S.</creatorcontrib><creatorcontrib>Arlicot, C.</creatorcontrib><creatorcontrib>Tournamille, J. F.</creatorcontrib><creatorcontrib>Viaud-Massuard, M. C.</creatorcontrib><creatorcontrib>Elfakir, C.</creatorcontrib><creatorcontrib>Antier, Daniel</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>قاعدة دراسات المرأة - e-Marefa Women Studies</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Respaud, Renaud</au><au>Gaudy, A. S.</au><au>Arlicot, C.</au><au>Tournamille, J. F.</au><au>Viaud-Massuard, M. C.</au><au>Elfakir, C.</au><au>Antier, Daniel</au><au>Horne, Andrew</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Implementation Study of Patient-Ready Syringes Containing 25 mg/mL Methotrexate Solution for Use in Treating Ectopic Pregnancy</atitle><jtitle>BioMed research international</jtitle><addtitle>Biomed Res Int</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>2014</volume><issue>2014</issue><spage>1</spage><epage>4</epage><pages>1-4</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract>Background. Ectopic pregnancy (EP) is a significant cause of morbidity and mortality during the first trimester of pregnancy. Small unruptured tubal pregnancies can be treated medically with a single dose of methotrexate (MTX). Objective. The aim of this study was to evaluate the stability of a 25 mg/mL solution of MTX to devise a secure delivery circuit for the preparation and use of this medication in the management of EP. Method. MTX solutions were packaged in polypropylene syringes, stored over an 84-day period, and protected from light either at +2 to +8°C or at 23°C. We assessed the physical and chemical stability of the solutions at various time points over the storage period. A pharmaceutical delivery circuit was implemented that involved the batch preparation of MTX syringes. Results. We show that 25 mg/mL MTX solutions remain stable over an 84-day period under the storage conditions tested. Standard doses were prepared, ranging from 50 mg to 100 mg. The results of this study suggest that MTX syringes can be prepared in advance by the pharmacy, ready to be dispensed at any time that a diagnosis of EP is made. Conclusion. The high stability of a 25 mg/mL MTX solution in polypropylene syringes makes it possible to implement a flexible and cost-effective delivery circuit for ready-to-use preparations of this drug, providing 24-hour access and preventing treatment delays.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Puplishing Corporation</pub><pmid>24900977</pmid><doi>10.1155/2014/689308</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2314-6133 |
| ispartof | BioMed research international, 2014-01, Vol.2014 (2014), p.1-4 |
| issn | 2314-6133 2314-6141 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4037123 |
| source | MEDLINE; PubMed Central Open Access; Wiley Online Library (Open Access Collection); PubMed Central; Alma/SFX Local Collection |
| subjects | Accuracy Care and treatment Complications and side effects Dihydrofolate reductase Dilution Dosage and administration Drug dosages Drug Packaging - methods Drug Stability Drug therapy Female Good Manufacturing Practice Health aspects Hospitals Humans Medical treatment Methotrexate Methotrexate - chemistry Methotrexate - therapeutic use Patients Pharmaceutical Solutions - chemistry Pharmaceutical Solutions - therapeutic use Pharmaceuticals Pharmacy Polypropylenes - chemistry Pregnancy Pregnancy complications Pregnancy, Ectopic Pregnancy, Ectopic - drug therapy Prevention Syringes |
| title | Implementation Study of Patient-Ready Syringes Containing 25 mg/mL Methotrexate Solution for Use in Treating Ectopic Pregnancy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T20%3A16%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Implementation%20Study%20of%20Patient-Ready%20Syringes%20Containing%2025%E2%80%89mg/mL%20Methotrexate%20Solution%20for%20Use%20in%20Treating%20Ectopic%20Pregnancy&rft.jtitle=BioMed%20research%20international&rft.au=Respaud,%20Renaud&rft.date=2014-01-01&rft.volume=2014&rft.issue=2014&rft.spage=1&rft.epage=4&rft.pages=1-4&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2014/689308&rft_dat=%3Cgale_pubme%3EA427024063%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1547924659&rft_id=info:pmid/24900977&rft_galeid=A427024063&rfr_iscdi=true |